Content section
Scientific Digest
Scientific Digest reviews peer-reviewed research relevant to private clinic care, prescribing and patient safety. The focus is not the headline alone, but what the evidence changes for regulation, informed consent and clinical governance.
-
GLP-1 exposure in early pregnancy: new study
A new claims study assessed GLP-1 continuation in early pregnancy, finding no definitive risk increase but wide uncertainty around several important outcomes.
-
Setting changes the odds after cosmetic Botox
A UK survey of 919 cosmetic Botox patients linked treatment setting, injector role and undisclosed products with different odds of reported adverse events.
-
UK study compares semaglutide and dulaglutide
A UK primary-care cohort found greater one-year HbA1c and weight reductions with semaglutide than dulaglutide, with comparable safety overall.
-
GLP-1 and mental health: new genetic evidence
A genetic study linked GLP-1 receptor activation to lower depression and bipolar risk. MHRA and EMA reviews found no causal link to suicidal thoughts.
-
GLP-1 eye risk: what the new review found
New observational evidence found no overall increase in ocular disorders, but uncertainty and the MHRA semaglutide warning still matter for clinics.
-
PJ analysis: online pharmacy weight loss prescribing safety
Research on safety risks in online pharmacy weight-loss prescribing and how it connects to GPhC enforcement.
-
Major review confirms GLP-1 safety for weight loss
A Nature Medicine review of 56 trials covering semaglutide and tirzepatide, with implications for UK clinic prescribing.
-
New study maps UK aesthetic medicine workforce
The first national workforce mapping study and what it adds to the case for cosmetic-procedure licensing.
-
4.9 million UK adults have used GLP-1 drugs, study finds
New prevalence evidence on UK GLP-1 use and the implications for advertising enforcement and pharmacy safeguards.